ATE313325T1 - Indolcaroboxylsäure als thyroidrezeptor-liganden - Google Patents

Indolcaroboxylsäure als thyroidrezeptor-liganden

Info

Publication number
ATE313325T1
ATE313325T1 AT02256536T AT02256536T ATE313325T1 AT E313325 T1 ATE313325 T1 AT E313325T1 AT 02256536 T AT02256536 T AT 02256536T AT 02256536 T AT02256536 T AT 02256536T AT E313325 T1 ATE313325 T1 AT E313325T1
Authority
AT
Austria
Prior art keywords
indolcaroboxylic
acid
receptor ligand
thyroid receptor
thyroid
Prior art date
Application number
AT02256536T
Other languages
English (en)
Inventor
Gary Eric Pfizer Global Aspnes
Yuang-Ching Phoebe Chiang
Road
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE313325T1 publication Critical patent/ATE313325T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02256536T 2001-09-26 2002-09-20 Indolcaroboxylsäure als thyroidrezeptor-liganden ATE313325T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32538501P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
ATE313325T1 true ATE313325T1 (de) 2006-01-15

Family

ID=23267668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02256536T ATE313325T1 (de) 2001-09-26 2002-09-20 Indolcaroboxylsäure als thyroidrezeptor-liganden

Country Status (9)

Country Link
US (1) US6723744B2 (de)
EP (1) EP1297833B1 (de)
JP (1) JP2003160559A (de)
AT (1) ATE313325T1 (de)
BR (1) BR0203877A (de)
CA (1) CA2404848C (de)
DE (1) DE60208132T2 (de)
ES (1) ES2253495T3 (de)
MX (1) MXPA02009472A (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082271A2 (en) * 2002-04-03 2003-10-09 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
GB0219022D0 (en) * 2002-08-15 2002-09-25 Karobio Ab Novel thyromimetic compounds
JP2006506366A (ja) * 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
JP2006519229A (ja) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
JP5047940B2 (ja) * 2005-03-12 2012-10-10 ユニリーバー・ナームローゼ・ベンノートシヤープ アミノ−オキソ−インドール−イリデン化合物を含む頭髪および／または頭皮ケア組成物
EP2082726A3 (de) * 2005-03-12 2009-09-02 Unilever PLC Haar- und/oder Kopfpflegezusammensetzungen mit Flavonoidverbindungen
BRPI0608030A2 (pt) * 2005-03-12 2009-11-03 Unilever Nv usos de um composto de terpenóide
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
CA2606499C (en) * 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
GB0610322D0 (en) * 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
EP2036887A1 (de) 2006-06-28 2009-03-18 Sanwa Kagaku Kenkyusho Co., Ltd Neues 6-5-bicyclisches heterocyclisches derivat und medizinische verwendung davon
US8021649B2 (en) 2007-02-22 2011-09-20 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
US20080206156A1 (en) * 2007-02-22 2008-08-28 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
PL2695611T3 (pl) 2012-08-06 2015-03-31 Dr August Wolff Gmbh & Co Kg Arzneimittel Eprotirom do stosowania w profilaktyce i/lub leczeniu zaburzeń włosów oraz jego kompozycje
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
CN106883153B (zh) * 2017-04-11 2018-11-13 河南工业大学 一种2-磺酰基-1,4-二酚衍生物的制备方法
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
EP3768690A4 (de) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US5232947A (en) 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
ES2108855T3 (es) 1992-07-21 1998-01-01 Ciba Geigy Ag Derivados de acido oxamico como agentes hipocolesteremicos.
DE19808267A1 (de) 1998-02-27 1999-09-02 Messer France Sa Befüll- und Entnahmemodul für ein Kühlmodul und Verfahren zum Befüllen eines Kühlmoduls
GB9816935D0 (en) 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
NZ513449A (en) 1999-03-01 2004-02-27 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands
ES2234523T3 (es) 1999-03-01 2005-07-01 Pfizer Products Inc. Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos.
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
CA2375822A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Substituted biaryl ether compounds
JP2003500432A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ジフェニルエーテル誘導体を用いて脱毛症を処置する方法
MXPA01012494A (es) 1999-06-01 2002-07-02 Univ Texas Southwestern Med Ct Metodo para tratar perdida capilar con el uso de compuestos sulfonil tiromimeticos.
CA2374266A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
JP2003500431A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター 毛髪の損失を治療する方法
CA2403806A1 (en) * 2000-03-23 2002-09-20 Bayer Aktiengesellschaft Indoles for treating diseases that can be treated using thyroid hormones
ATE310733T1 (de) * 2000-04-21 2005-12-15 Pfizer Prod Inc Thyroid-rezeptorliganden
JP2004517851A (ja) * 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体

Also Published As

Publication number Publication date
ES2253495T3 (es) 2006-06-01
DE60208132D1 (de) 2006-01-26
EP1297833B1 (de) 2005-12-21
EP1297833A1 (de) 2003-04-02
CA2404848C (en) 2006-07-04
US20030078289A1 (en) 2003-04-24
CA2404848A1 (en) 2003-03-26
DE60208132T2 (de) 2006-07-20
BR0203877A (pt) 2003-09-16
JP2003160559A (ja) 2003-06-03
MXPA02009472A (es) 2003-03-31
US6723744B2 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
DE60208132D1 (de) Indolcaroboxylsäure als Thyroidrezeptor-Liganden
CA2403902A1 (en) Malonamic acids and derivatives thereof as thyroid receptor ligands
ATE310733T1 (de) Thyroid-rezeptorliganden
DK1088819T3 (da) 6-azauracilderivater som thyroidreceptorligander
CA2363145A1 (en) Oxamic acids and derivatives as thyroid receptor ligands
PT1033364E (pt) Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
WO1998047505A9 (fr) Antagoniste de recepteur de neuropeptide y
CA2332066A1 (en) Tetrazole compounds as thyroid receptor ligands
BR0313109A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina de cxc
DE69816731D1 (de) Benzofuranon-derivate und verfahren zu ihrer herstellung
PT814791E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
EP1207157A4 (de) Substituierte benzylthiazolidin-2,4-dion derivate
DE60228429D1 (de) Medizinische zusammensetzung, die ein 1,3-thiazinderivat enthält
DE60227655D1 (de) Pyrrolderivat
AR028981A1 (es) Proceso para la preparacion de terbuconazol
EP1897881A8 (de) Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen
TR200003299T2 (tr) Oksiiminoalkanoik asit türevleri.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties